Literature DB >> 11455163

Ulcerative sarcoidosis successfully treated with apligraf.

M Streit1, L M Böhlen, L R Braathen.   

Abstract

The case of a 73-year-old female patient is reported with a 25-year-long history of widespread cutaneous sarcoidosis without any known extracutaneous manifestations. The skin manifestations started with erythematous and plaque-like lesions that had ulcerated on the legs for the last half-year. A relevant venous insufficiency or other etiology of the ulcers could not be found. Histology from lesions of the trunk and from the surroundings of the ulcers revealed the typical noncaseating granulomas. A systemic involvement could not be observed; leukopenia and a slightly elevated angiotensin-converting enzyme level in the serum were found. Topical steroids did not prove successful on the ulcers. Apligraf, a bilayered skin equivalent, was transplanted twice on the ulcers leading to complete closure within 3 months. A therapy with systemic steroids could thus be avoided. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11455163     DOI: 10.1159/000051685

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  3 in total

1.  [Uncommon cutaneous ulcerative and systemic sarcoidosis. Successful treatment with hydroxychloroquine and compression therapy].

Authors:  D Meyersburg; M P Schön; H P Bertsch; C S Seitz
Journal:  Hautarzt       Date:  2011-09       Impact factor: 0.751

2.  Multisystemic Sarcoidosis Presenting With Leg Ulcers, Pancytopenia, and Polyserositis Was Successfully Treated With Glucocorticoids: A Case Report and Literature Review.

Authors:  Xin Qiao; Shan He; Abdullah Altawil; Qiu-Yue Wang; Jian Kang; Wen-Yang Li; Yan Yin
Journal:  Front Med (Lausanne)       Date:  2022-02-15

Review 3.  A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers.

Authors:  Larissa Zaulyanov; Robert S Kirsner
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.